We could hypothesize that masitinib could reduce depression symptoms in mastocytosis by two pathways: i. by blocking mediators secreted by mast cells involved in increasing permeability of the BBB and brain inflammation; ii. by reducing mast cells numbers in the thalamus or other structures of the limbic system through its direct effect on KIT and Lyn. The gene discussed is KIT; the disease is major depressive disorder.